CTIS2023-504799-94-00招募中1 期
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria - EP-262-201
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age 18 to 80 years, Documented history of chronic spontaneous urticaria (CSU) with a UAS7 greater than or equal to 16 despite stable treatment with H1 antihistamine consistent with standard of care, Must be on a stable dose of H1 antihistamine up to 4 times the approved dose per local treatment guidelines
排除标准
- •Urticaria with a clear underlying etiology other than CSU, Urticaria with a clearly defined or sole trigger (chronic inducible urticaria), Other active skin diseases associated with chronic pruritus (eg, atopic dermatitis, bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis)
研究者
相似试验
进行中（未招募）
1 期
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for the Reduction of Localized Subcutaneous Fat in the Submental AreaEUCTR2007-006303-21-GBKythera Biopharmaceuticals, Inc.60
进行中（未招募）
1 期
Efficacy and Safety Study of BMS-986142 in Patients with Moderate to Severe Rheumatoid ArthritisEUCTR2015-002887-17-ATBristol-Myers Squibb International Corporation610
进行中（未招募）
1 期
Efficacy and Safety Study of BMS-986142 in Patients with Moderate to Severe Rheumatoid ArthritisModerate to Severe Rheumatoid Arthritis with an Inadequate Response to Methotrexate With or Without TNF InhibitorsMedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2015-002887-17-FRBristol-Myers Squibb International Corporation508
撤回
2 期
Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects with Moderate to Severe Rheumatoid Arthritis with an Inadequate Response to Methotrexate with or without TNF Inhibitors.Chronic inflammation of the joints10003816Rheumatoid arthritisNL-OMON43673Bristol-Myers Squibb10
进行中（未招募）
1 期
Efficacy and Safety Study of BMS-986142 in Patients with Moderate to Severe Rheumatoid ArthritisEUCTR2015-002887-17-ESBristol-Myers Squibb International Corporation610